Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDI5ORGL47)
  Drug Name Alfuzosin Drug Info Riociguat Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Vasodilator Agents
  Structure

 Mechanism of Alfuzosin-Riociguat Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Alfuzosin Riociguat
      Mechanism Antihypertensive agent
Alpha-1 adrenergic receptor  Antagonist 		Hypotensive effects
Soluble guanylyl cyclase  Agonist
      Key Mechanism Factor 1
Factor Name Adrenergic receptor alpha-1 Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
    Click to Show/Hide
      Key Mechanism Factor 2
Factor Name Guanylate cyclase soluble Structure Sequence
Protein Family Adenylyl cyclase class-4/guanylyl cyclase family
Protein Function
Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Alfuzosin and Riociguat 

Recommended Action
      Management Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.

References
1 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.